MedTech logo

t: 0161 820 8440



MedTECH Tenant Phagenesis raises 2 million investment

Phagenesis has raised £2m of investment to support the development of a new class of treatments for stroke patients who suffer from dysphagia.

Specialising in developing technology for the treatment of swallowing dysfunction, the company now reports that it has been successful in attracting funding from a number of experienced investors.

Phagenesis CEO Daniel Green said 'To raise £2m in a few months in the current economic climate is a remarkable achievement and was made possible because the technology has accumulated substantial amounts of exicing data in human subjects.'

back to news listing

Supported by:

Central Manchester University Hospitals logoManchester Science Parks logoTrusTECH logo